MYO-MRI Diagnostic Protocols in Genetic Myopathies


Jodi Warman Chardona, Jordi Díaz-Manera, Giorgio Tasca, Carsten G. Bönnemann, David Gómez-Andrés, Arend Heerschap, Eugenio Mercurii, Francesco Muntoni, Anna Pichiecchio, Enzo Ricci, Maggie C. Walter, Michael Hanna, Heinz Jungbluth, Jasper M. Morrow, Roberto Fernández Torrón, Bjarne Udd, John Vissing, Tarek Yousry, on behalf of the MYO-MRI Working Group, Susana Quijano-Roy, Volker Straub, Robert Carlier

Whole-body magnetic resonance imaging (WBMRI) has emerged as a useful imaging tool in diagnosing and characterizing the progression of myopathies and muscular dystrophies. WBMRI indications and diagnostic efficacy are becoming better defined with the increasing number of cases, publications and discussions within multidisciplinary working groups. Advanced WBMRI protocols are rapid, lower cost, and well-tolerated by patients. Accurate interpretation of muscle WBMRI requires a detailed knowledge of muscle anatomy and differential pattern of involvement in muscle diseases. With the surge in recently identified novel genetic myopathies, WBMRI will become increasingly useful for phenotypic validation of genetic variants of unknown significance. In addition, WBMRI will be progressively used as a biomarker for disease progression and quantify response to therapy with the emergence of novel disease modifying treatments. This review outlines WBMRI indications and updates refined protocols and provides a comprehensive overview of the diagnostic utility and suggested methodology of WBMRI for pediatric and adult patients with muscle diseases.

Published: 16 September 2019
Journal: Neuromuscular Disorders, volume Online


The ERNs are co-funded by the
European Union (Health Programme and CEF)

EU Commission

“EURO-NMD is one of the 24 European Reference Networks (ERNs) approved by the ERN Board of Member States. The ERNs are co-funded by the European Union (Health Programme and CEF).
For more information about the ERNs and the EU health strategy,
please visit